|
|
|
Insulet Corporation (NASDAQ: PODD) |
|
|
|
| |
Insulet Corporation Outlook |
On August 9 2024 the Insulet Corporation provided following guidance
nnInsulet Corporationnn Reports Impressive Revenue Growth for Second Quarter 2024
nnACTON, Massachusettsnn – Insulet Corporation (NASDAQ: PODD), a preeminent innovator in tubeless insulin pump technology known for its Omnipod product line, has released its financial results for the second quarter of 2024, showcasing a notable revenue increase.
For the period ending June 30, 2024, Insulet achieved a remarkable revenue of $488.5 million, reflecting a 23.2% rise compared to $396.5 million reported during the same quarter the previous year. When adjusted for constant currency, the revenue growth stands even higher at 23.4%. This significant uptick not only highlights the company’s robust performance but also surpasses their prior financial guidance, which anticipated an 18% growth rate in constant currency.
The results underscore Insulet's strong market position and commitment to delivering innovative solutions in diabetes management. The company’s ability to exceed expectations reinforces its strategic initiatives and operational capabilities in a constantly evolving healthcare landscape.
Insulet’s leadership expressed confidence in the trajectory of the business, buoyed by the growing acceptance of their Omnipod technology among patients and healthcare providers alike. With these results, the company continues to solidify its status as a leader in the industry, paving the way for future growth opportunities.,
|
On May 10 2024 the Insulet Corporation provided following guidance
higher than expected demand for the Omnipod insulin pump system. Gross margin for the first quarter of 2024 was 65.9%, compared to 66.4% in the prior year, primarily driven by increased investments in manufacturing and distribution capacity to support future growth.
Operating income for the first quarter of 2024 was $82.5 million, or 18.7% of revenue, compared to $71.5 million, or 19.9% of revenue in the prior year. Net income for the first quarter of 2024 was $60.2 million, or $0.94 per share, compared to $53.8 million, or $0.84 per share in the prior year.
We are very pleased with our strong start to 2024, driven by robust demand for our Omnipod insulin pump system, said Shacey Petrovic, President and Chief Executive Officer. Our focus on expanding access to insulin pump therapy and providing innovative solutions for people with diabetes is resonating with customers and driving our growth.
Insulet Corporation continues to expect full year 2024 revenue to be in the range of $1.74 billion to $1.78 billion, representing growth of 16% to 19% in constant currency. The Company also reiterated its full year 2024 operating income margin guidance of approximately 17% to 19%.
In conclusion, Insulet Corporation's strong first quarter performance and positive outlook for the full year 2024 reflect the Company's continued commitment to innovation and growth in the diabetes management market.
|
On February 22 2024 the Insulet Corporation provided following guidance
Insulet Corporation, a leading provider of tubeless insulin pump technology under the Omnipod brand, has reported a significant increase in revenue for the full year 2023. The company saw a 30% increase in revenue, amounting to $1.7 billion, compared to $1.3 billion in the previous year. When adjusted for constant currency, the revenue growth was 29.6%, exceeding the company's guidance range of 26% to 27%.
In the fourth quarter of 2023, Insulet experienced a year-over-year revenue increase of 38%, or 37% in constant currency. These strong financial results demonstrate the company's continued growth and success in the market. With its innovative products and commitment to providing quality healthcare solutions for individuals with diabetes, Insulet is well-positioned for continued success in the future.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
